RecruitingOvarian Cancer
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Eligible age
18+ yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.
Sponsor: Theolytics Limited
You may not qualify if…
- ✕ Prior anti-cancer treatment or Investigational Product within 28 days or 5 half-lives, prior to first dose of THEO-260.
- ✕ Prior treatment with a group B adenovirus.
- ✕ Radiation therapy within 4 weeks of first dose of THEO-260
- ✕ Clinical evidence of cerebral metastases or Central Nervous System (CNS) involvement including leptomeningeal disease. Patients with previous cerebral metastases must have no evidence of progression or haemorrhage after treatment.
- ✕ Uncontrolled pleural effusion or pericardial effusion requiring recurrent drainage procedures (as defined as once monthly or more frequently).
- ✕ Prior pneumonitis or history of interstitial lung disease.
- ✕ Confirmed QTcF ≥470 ms on screening 12-lead ECG or history of Torsades de Pointes or history of congenital long QT syndrome.
- ✕ Concomitant medications that prolong the QTc interval and/or increase the risk for Torsades de Pointes.
Where it's recruiting
Texas
Houston
Source: ClinicalTrials.gov · NCT07211659 · last updated 2026-04-22